Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Venetoclax with Dexamethasone for Rel/Ref Myeloma with t(11;14)
In the CANOVA study, venetoclax-dexamethasone did not significantly improve progression-free survival compared to pomalidomide-dexamethasone in patients with t(11;14)-positive rela
New Protocol: Tucatinib with Trastuzumab and Pertuzumab for Maintenance in HER2-Positive Breast Cancer
The study found that adding tucatinib to trastuzumab and pertuzumab significantly improved progression-free survival compared with placebo, with a hazard ratio of 0.641. Tucatinib
New Protocol: Tiragolumab and Atezolizumab with Chemotherapy in 1st Line Advanced Esophageal SCC
This phase 3 trial demonstrated that the combination of tiragolumab and atezolizumab with chemotherapy significantly improved progression-free and overall survival compared to chem
New Protocol: Talquetamab + Teclistamab for Extramedullary Myeloma
Talquetamab plus teclistamab achieved a high response rate of 79% in patients with drug-resistant, true extramedullary myeloma. Median progression-free survival was 15.4 months and
New Reference: Tafasitamab with Rituximab/Lenalidomide for Rel/Ref Follicular Lymphoma
The addition of tafasitamab to lenalidomide and rituximab significantly improved progression-free survival and overall response rate compared to the placebo group. The treatment wa
New Drug: Suvemcitug for Ovarian Cancer
The SCORES trial demonstrated that suvemcitug, when added to chemotherapy, significantly improved progression-free and overall survival in women with platinum-resistant ovarian can
New Drug: Savolitinib with Osimertinib for EGFR-Mutated, MET-Amplified NSCLC
Savolitinib-osimertinib significantly prolonged progression-free survival compared to chemotherapy in EGFR mutation-positive, MET-amplified Chinese NSCLC patients. The combination
New Indication: Ribociclib + Letrozole for Low-Grade Serous Ovarian Cancer
Ribociclib plus letrozole achieved a 30.6% overall response rate, with a median progression-free survival of 14.5 months and median overall survival of 44.5 months. The regimen dem
New Reference: Pirtobrutinib vs. Ibrutinib in CLL
Pirtobrutinib was shown to be non-inferior to ibrutinib in terms of overall response rate and had a more favorable safety profile, with lower rates of adverse cardiac events. The s
